Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 77

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 77
---
 “—Opinion of STAAR’s Financial Advisor.” The written opinion delivered by Citi is attached to this proxy statement as Annex B.

Following discussion, and after taking into consideration the information provided by and discussed with STAAR management and advisors,
including the factors described below in greater detail in “—Reasons for the Merger,” the Board unanimously determined that the Merger Agreement and the transactions contemplated thereby, including the Merger, on the terms
and subject to the conditions set forth in the Merger Agreement, are advisable, fair to and in the best interests of STAAR and its stockholders, approved, adopted and declared advisable the execution and delivery of, and entry into, the Merger
Agreement, and directed that the Merger Agreement be submitted to the STAAR stockholders for adoption at the Special Meeting.

Prior to
executing the Merger Agreement, Mr. Farrell reached out to each of Party A and Party B inviting them to make a proposal for STAAR’s review. Neither responded prior to the execution of the Merger Agreement and, following the execution of
the Merger Agreement, Party B sent another email expressing interest in a potential transaction with STAAR without providing any indication of its views on valuation, timing, diligence requirements, financing capability or transaction structure.

Following the meeting of the Board on August 4, 2025, the Merger Agreement was executed on the evening of August 4, 2025.
Before the opening of financial markets in New York on August 5, 2025, STAAR filed a current report on Form 8-K announcing the transaction, and the parties issued a joint press release in regards to the
same.

On August 8, 2025, Alcon filed a current report on Form 6-K announcing the
transaction.

Also on August 8, 2025, Broadwood filed a Schedule 13D/A with the SEC disclosing beneficial ownership of 27.3% of
the outstanding STAAR common stock. Broadwood’s filing indicated it had not decided whether to vote in favor of the Merger, against the Merger, or in favor of a superior offer. Further, the Schedule 13D/A noted that Broadwood would be seeking
additional documents and information relating to the process that led to the signing of the Merger Agreement to inform its voting decision and was planning to explore strategic alternatives to the Merger.

On September 2, 2025, Broadwood filed a Schedule 13D/A and issued a related press